Aurobindo Stock - weekly review and sector backdrop for pharma

Aurobindo Pharma stock ended the week with robust technical momentum after recent gains. This Sunday review looks at the past week’s key moves, the wider Indian pharma sector, and where the shares currently trade on the NSE.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/21/2026, 20:41 UTC. Details in the imprint.

Aurobindo Pharma (INE406A01037) remains one of the actively watched large-cap Indian generics names on the National Stock Exchange. This Sunday, the focus is on a weekly review of the stock and its peer group rather than on a single fresh corporate announcement.

How Aurobindo shares performed this week

Aurobindo Pharma shares showed mixed but ultimately positive momentum over the past trading week, with notable swings in both price and derivatives positions according to MarketsMojo data. The stock recorded an intraday low on 06/15 after a sharp 4.43% decline that day.

Derivatives activity picked up at the same time, with open interest in Aurobindo futures rising about 12.9% on 06/15, signaling renewed positioning by market participants. After that, technical momentum gradually improved from neutral to mildly bullish and then turned clearly bullish toward the week’s end.

Weekly gains and peer comparison in pharma

On the final trading day of the week, cited as 06/19, Aurobindo Pharma shares reached a weekly high around INR 1,497.85 and closed up roughly 1.5% versus the previous session. Across the full week, MarketsMojo notes a gain of about 1.7% for the stock.

That performance comes on top of a strong year-to-date run of roughly 26.8% in Aurobindo stock, which leaves it broadly in line with or modestly ahead of several large Indian pharma peers this year. The stock also benefits from robust institutional ownership, underscoring continued interest from long-only investors and funds.

Sector backdrop and valuation signals

The broader Indian pharmaceutical sector continues to be supported by steady export demand for generics and active pharmaceutical ingredients, even as pricing remains competitive in key markets like the United States. In this setting, Aurobindo’s diversified product mix offers some cushion against single-market volatility.

MarketsMojo currently rates Aurobindo Pharma as a “Hold,” with this recommendation last updated on 05/25/2026, suggesting neither extreme bullishness nor pronounced caution from that particular research provider. For now, that fits a picture of a stock where recent price strength balances valuation and sector risks.

The product engine behind Aurobindo

Aurobindo Pharma’s core business centers on generic oral solid formulations, injectable drugs and active pharmaceutical ingredients for cardiovascular, central nervous system, anti-infective and other therapeutic areas. The company also supplies key antibiotics and antivirals to international markets through its formulations and API segments.

Where the stock trades today

The shares of Aurobindo Pharma (INE406A01037) trade on the National Stock Exchange of India at around INR 1,498.00 as of 06/21/2026, 20:30 IST.

Key facts on Aurobindo Pharma stock

• Company: Aurobindo Pharma Ltd.
• ISIN: INE406A01037
• WKN: 588814
• Ticker: AUROPHARMA
• Venue: NSE
• Price (as of 06/21/2026, 20:30 IST): 1,498.00 INR
• Market cap: 878,000,000,000 INR (as of 06/21/2026)
• Sector / Industry: Pharmaceuticals / Generic drugs
• Index membership: Nifty 50
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.